ARS Pharmaceuticals (SPRY) Cash from Financing Activities (2020 - 2026)

ARS Pharmaceuticals has reported Cash from Financing Activities for 7 years, with the latest figure at $159000.0 in Q1 2026.

• Quarterly Cash from Financing Activities fell 78.07% year-over-year to $159000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104.0 million (up 42.77% YoY) and the FY2025 annual result came in at $104.6 million, up 44.47% from the prior year.
• Cash from Financing Activities fell to $159000.0 in Q1 2026 per SPRY's latest filing, from $1.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $193.8 million in Q4 2022 and troughed at -$1.6 million in Q3 2022.
• A 5-year average of $22.0 million and a median of $921000.0 in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities sank 1151.35% in 2022, then surged 14612.5% in 2025.
• Over 5 years, Cash from Financing Activities stood at $193.8 million in 2022, then plunged by 99.07% to $1.8 million in 2023, then soared by 3828.86% to $70.9 million in 2024, then slumped by 98.41% to $1.1 million in 2025, then slumped by 85.94% to $159000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $159000.0, $1.1 million, and $100.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.